This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM et al. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization (WHO) Classification of Tumours, vol. 1. IARC Press: Lyon, France, 2001, pp 291–302.
Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603–625.
Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol 2014; 25: 1691–1700.
Mital A, Piskorz A, Lewandowski K, Wasag B, Limon J, Hellmann A . A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011; 86: 531–535.
Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotar K, Hermine O et al. Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. Blood 2014; 124: 636.
Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014; 32: 3264–3274.
Krauth MT, Bohm A, Agis H, Sonneck K, Samorapoompichit P, Florian S et al. Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. Exp Hematol 2007; 35: 108–116.
Valent P, Akin C, Escribano L, Födinger M, Hatmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435–453.
van Der Velden VH, Te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197–3204.
Orfao A, Escribano L, Villarrubia J, Velasco JL, Cerveró C, Ciudad J et al. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples. Identification and enumeration. Am J Pathol 1996; 149: 1493–1499.
Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L et al. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol 2010; 149: 376–382.
Jeong DK, Fauman K, Ross C, Akin C, Mody R . Successful treatment of systemic mastocytosis associated with AML-M2, t (8: 21) in a child using MRC-based AML chemotherapy along with gemtuzumab. J Allergy Clin Immunol 2007; 119, (Suppl 1) S207 (abstract 814).
Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003; 27: 635–641.
Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013; 121: 2393–2401.
Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.
Acknowledgements
This work was supported by grants from Fundación Mutua Madrileña (Madrid, Spain), Asociación Española de Enfermos de Mastocitosis (Madrid, Spain), Fundación Ramón Areces, Madrid, Spain (grant CIVP16A1806), Red Temática de Investigación Cooperativa en Cancer (RTICC) of the Instituto de Salud Carlos III, Ministry of Economy and Competitivity, Madrid, Spain (grant RD12/0036/0048, FEDER), Fundación Samuel Solorzano, Salamanca, Spain (grant FS/22-2014), and the Charles and Ann Johnson Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Alvarez-Twose, I., Martínez-Barranco, P., Gotlib, J. et al. Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. Leukemia 30, 1753–1756 (2016). https://doi.org/10.1038/leu.2016.30
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.30
This article is cited by
-
Identification of a leukemia-initiating stem cell in human mast cell leukemia
Leukemia (2019)
-
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis
Current Hematologic Malignancy Reports (2018)